Primary Orbital Melanoma: A Systematic Review of Clinical Characteristics, Management and Outcomes.

Int Ophthalmol ClinSep 24, 2026 (epub)

Antonia Vieira Vender, Kaveh Vahdani, Geoffrey E Rose

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated clinical characteristics, management, and outcomes of 112 patients with histopathologically confirmed primary orbital melanoma (POM). The study found that local recurrence occurred in 21% and metastasis in 39% of cases. Notably, adjuvant radiotherapy was associated with improved survival (HR=0.23; P=0.006).

Key findings

  • Local recurrence occurred in 21% of patients and metastasis in 39%.
  • 5-year overall survival showed a trend favoring melanocytosis-associated tumors (74% vs 44%; P=0.058).
  • Adjuvant radiotherapy was associated with improved survival (HR=0.23; P=0.006).
  • Globe-sparing surgery was performed in 47% of cases.

Why it matters

Understanding the clinical characteristics and outcomes of primary orbital melanoma can guide treatment decisions and improve patient management. The findings highlight the potential benefits of adjuvant radiotherapy and the importance of tumor classification.

Source

Published in Int Ophthalmol Clin. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Ophthalmology

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.